TG Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• TG Therapeutics Inc TGTX.OQ reported quarterly adjusted earnings of $2.43​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 2 cents. The mean expectation of eight analysts for the quarter was for earnings of 22 cents per share. Wall Street expected results to range from 11 cents to 33 cents per share.

• Revenue rose 92.8% to $161.71 million from a year ago; analysts expected $152.17 million.

• TG Therapeutics Inc's reported EPS for the quarter was $2.43​.

• The company reported quarterly net income of $390.9 million.

• TG Therapeutics Inc shares had fallen by 3.7% this quarter and gained 15.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.6% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for TG Therapeutics Inc is $49.00, about 29% above its last closing price of $34.78

This summary was machine generated from LSEG data November 3 at 03:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)